Efficacy, Safety, and Hematologic Recovery Following Intravenous Ferric Carboxymaltose in Patients with Iron Malabsorption-Related Iron Deficiency Anemia: A Prospective Clinical Study
Prospective clinical study assesses recovery from iron deficiency anemia in patients with iron malabsorption, suggesting efficacy of IV ferric carboxymaltose treatment.
Key Points
This study aims to evaluate the efficacy, safety, and quality of life impact of intravenous ferric carboxymaltose in treating iron deficiency anemia due to iron malabsorption.
Single-center, prospective observational study with 37 adults having autoimmune gastritis, celiac disease, or gastric surgery-related IDA receiving IV ferric carboxymaltose.
Endpoints included safety tolerability, hemoglobin normalization for IDA recovery, and quality of life impact assessed through QoL-SF12 questionnaire at baseline and after 12 weeks.
Complete blood count and iron status were evaluated at baseline, 4 weeks, and 12 weeks post-treatment.
IDA recovery was achieved in 26 (70.3%) patients at 4 weeks and 29 (78.4%) at 12 weeks.
Significant increases in hemoglobin from 10.8 g/dL to 12.7 g/dL at 4 weeks and to 13.1 g/dL at 12 weeks (p < 0.05).
Only 2.7% experienced mild adverse events, indicating IV FCM is a safe treatment option.